A EMS suggested a business combination with the pharmaceutical company Hyperin a proposal that involves a public takeover offer (OPA) of up to 20% of Hypera shares for R$30 and the remainder in exchange for shares, informed the Brazil Journal and the Economic Value.
According to the investigations, the operation would give EMS control of at least 60% of the pharmaceutical group, possibly exceeding 70% depending on adherence to the OPA.
READ MORE: Hypera makes adjustments in search of R$2.5 billion more in cash
If the merger goes ahead, it could create a pharmaceutical company with annual revenue of R$15.9 billion, with an operating profit (EBITDA) estimated at R$5 billion, with the majority of this coming from EMS, which today is a less indebted company. .
Talks for a possible merger have been taking place for more than a year, according to the findings, with direct conversations between Carlos Sanchez, the owner of EMS, with João Alves de Queiroz Filho and the Mexican Maiorem, the main shareholders of Hypera, which together own 36% of the company’s shares.
The assessment of people involved in the negotiation is that the combination could generate robust synergies and a company with a 17% market share, more than double the Eurofarmathe second largest in the country.
EMS is best known for the medicines Gerovital, Lacday and Balsamo Bengué, while Hypera owns labels such as Engov, Neosaldina and Benegripe. Hypera also owns Neo Química, the brand that gives its name to the Coritnhians stadium.
